Price
No data yet.
Social Signal Score
Analyst Ratings
32 analystsRevenue
$1.38B+168.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ronald F. Clarke
- Sector
- Technology
- Industry
- Software - Infrastructure
- Employees
- 10,500
- Beta
- 1.22
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.51
Financials
Revenue
$1.38B+168.4%Net Income
$378.42M+296.6%EBITDA
$722.88M+207.1%Free Cash Flow
$-735.05M-358.4%EPS (diluted)
$5.66+466.0%Shares Outstanding (diluted)
66.39M-30.3%Operating Expenses
$349.59MCash & Debt
$3.83BReturn of Capital
$706.53MRevenue by Segment (annual)
$4.24BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.53B | $1.07B | $15.23 |
| 2024 | $3.97B | $1.00B | $14.27 |
| 2023 | $3.76B | $981.89M | $13.42 |
| 2022 | $3.43B | $954.33M | $12.62 |
| 2021 | $2.83B | $839.50M | $10.23 |
| 2020 | $2.39B | $704.22M | $8.38 |
| 2019 | $2.65B | $895.07M | $10.36 |
| 2018 | $2.43B | $811.48M | $9.14 |
| 2017 | $2.25B | $740.20M | $8.12 |
| 2016 | $1.83B | $452.38M | $4.89 |
| 2015 | $1.70B | $362.43M | $3.94 |
| 2014 | $1.20B | $368.71M | $4.37 |
| 2013 | $895.17M | $284.50M | $3.48 |
| 2012 | $707.53M | $216.20M | $2.52 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from FLT's reported EPS growth of 14.8% a year over 13 years.
- EPS in 5 years
- $30.41
- Implied price
- $608.28
- Return from $303.26
- 14.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $302.42 — -0.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| 4.8% | -2.3% | 1.6% | 4.9% | 7.9% | 10.6% |
| 9.8% | 2.4% | 6.4% | 9.9% | 13.0% | 15.9% |
| 14.8% | 7.0% | 11.3% | 14.9% | 18.2% | 21.1% |
| 19.8% | 11.7% | 16.1% | 19.9% | 23.3% | 26.4% |
| 24.8% | 16.3% | 21.0% | 24.9% | 28.5% | 31.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·12d ago·Negative
Volatus Aerospace Releases Q3 2026 Financial Results MONTREAL, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSX:FLT) (OTCQX:TAKOF) (Frankfurt:A3DP5Y/ABB.F) ("Volatus" or "the Company"), a Canadian-headquartered global aerospace and defence company, is pleased to announce its financial results for the three and nine months ended September 30, 2026 (Q3 2026). All dollar figures are stated in Canadian dollars, unless otherwise indicated.
View source ↗ - Newsglobenewswire.com·17d ago·Negative
Volatus Aerospace to Announce Third Quarter 2026 Financial Results on November 10, 2026 MONTREAL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSX:FLT) (OTCQX:TAKOF) (Frankfurt:A3DP5Y/ABB.F) ("Volatus" or the "Company"), a Canadian-headquartered global aerospace and defence company, will release its financial results for the three and nine months ended September 30, 2026, on Tuesday, November 10, 2026, after market close.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3 T cell engager…
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
…arks Official Opening of Mirabel Facility as Canadian Manufacturing Operations Scale MIRABEL, Québec, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a global aerospace and defence company, today marked the official opening of its 53,000-square-foot manufacturing and systems integration facility in Mirabel, Québec, representing a significant expansion of the Company's Canadian production capacity and its ability…
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
…rcial programs that its expanding pipeline and sovereign capability increasingly within reach MONTREAL, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSX:FLT) (OTCQX:TAKOF) (Frankfurt: ABB.F) ("Volatus" or the "Company"), a Canadian-headquartered global aerospace and defence company, is pleased to announce its financial results for the three and six months ended June 30, 2026 (Q2 2026). All dollar figures are stated in Canadian dollars, unless otherwise indicated.
View source ↗
Earnings
Typical surprise -24.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$3.75 vs $6.56miss
- Fri, May 8$5.14 vs $5.73miss
- Fri, Feb 27$3.79 vs $5.94miss
- Wed, May 1$3.54 vs $4.10miss
Estimates and results for FLT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FLT officers and directors.
- Bought
- —
- Sold
- $47.6m
0 trades
6 trades
- King Alansold
- King Alansold
- Vickery Alissa Bsold
- Clarke Ronaldsold
- Clarke Ronaldsold
- King Alansold
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- April McClain Delaneyhouse · MD06 · disclosed Sep 10, 2026 (35d later)Sell$15,001 - $50,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 10, 2026 (38d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 10, 2026 (34d later)Sell$15,001 - $50,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (7d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (20d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (5d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (18d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (19d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 4, 2026 (4d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Apr 3, 2025 (21d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 21, 2025 (43d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 21, 2025 (27d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 21, 2025 (21d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 14, 2023 (43d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 14, 2023 (42d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
